Physician profile
Brian Mears
NPI 1164789392
$3,447.80
in general payments reported to CMS, 2019-2025
14 companies · $152 in 2025
The $152 reported for 2025 was more than what 84% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $153 · 2023: $2,296 · 2024: $649 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034 · Travel and Lodging: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.60 |
| Travel and Lodging | $1,063.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,728.58 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $451.45 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $302.65 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $230.01 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.47 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $126.22 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $125.94 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $98.33 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $50.69 | 2023-2024 | Auvelity |
| Corium, LLC | $49.97 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $41.04 | 2024 | |
| Vanda Pharmaceuticals INC. | $28.47 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.98 | 2023 | Quviviq |
| Tris Pharma INC | $15.00 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.